Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients

摘要: Patients with breast cancer receiving chemotherapy have an increased risk of infection mediated through a low number protective white blood cells (neutropenia). Neutropenia is common toxicity many agents and caused by the suppression bone marrow. The first sign usually fever, which indicates potentially life-threatening condition if it occurs during severe neutropenia (febrile (FN)). FN requires hospital care including administration intravenous antibiotics possible delays in continuation chemotherapy. Colony-stimulating factors (CSFs) are drugs administered order to prevent or reduce incidence duration neutropenia. This review included eight trials 2156 patients had randomly received CSFs placebo no treatment These were carried out between 1995 2008. Prophylactic significantly reduced developing 73%. estimated needed be treated one event was 12. Although significant decrease mortality all causes CSF therapy noted, there reduction infection-related mortality. There effect observed that planned schedules could better maintained decreased CSFs. Notably, need for yet frequently short-term adverse effects like pain injection-site reactions. There several limitations this analysis: only few included, these trials, disease stages treatments varied considerably. Moreover, trial authors defined their outcomes differently, making comparisons across studies difficult. Information on primary secondary not obtained from overall reporting quality low. Many dated hence did comply current recommendations. Overall, shown moderate evidence benefit prevention early weak substantiates further studies. treatment.